ERBB2 and inflammatory breast carcinoma: In 4 studies of chemotherapy plus targeted therapy, patients were treated with bevacizumab: the studies by Palazzo et al. [35] and Pierga et al. [36] of bevacizumab plus trastuzumab, mentioned in the preceding paragraph, and studies by Bertucci et al. and Nahleh et al. Pierga et al. [36] enrolled only HER2-positive IBC patients.